Dennis Slamon outlines the MONALEESA-3 findings showing that postmenopausal women with HR-positive, HER2-negative advanced breast cancer derive a survival advantage from combining the CDK4/6 inhibitor ribociclib with fulvestrant (1:47).
George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).
Rowan Chlebowski discusses the latest update from the Women’s Health Initiative Dietary Modification clinical trial showing the positive impact of a healthy diet on the risk of breast cancer death in postmenopausal women. He also touches upon how the metabolic syndrome may modify this risk (5:52).
Sara Hurvitz summarises the findings of the phase III MONALEESA-7 trial investigating the addition of ribociclib to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer (3:21).
A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.